--- title: "PolyPid (PYPD) news: delisting and offering" url: "https://aibio.space/companies/polypid/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "PYPD delisting and offering news: PolyPid says $14.5 million private placement restored Nasdaq equity compliance. PolyPid Ltd. (NASDAQ: PYPD), Israel." --- PYPD PolyPid Ltd. NASDAQ · Israel # PolyPid (PYPD) news PYPD delisting and offering news Financings · 2025-11-26 ## [PolyPid raises share sales program limit from $8,250,000 to $15,000,000](https://aibio.space/news/polypid-raises-share-sales-program-limit-8-250-000-15-000-000/) PolyPid can now sell up to $15,000,000 of ordinary shares through Oppenheimer & Co. Inc., up from $8,250,000, paying a 3.0% commission. Its shares closed at $3.68 on November 25, 2025, and the supplement does not say how much cash the company has. ## Latest PolyPid news 1. 2025-06-17 Financings [PolyPid agrees to $26.7 million in warrant exercises at $3.50 per share](https://aibio.space/news/polypid-agrees-26-7-million-warrant-exercises-3-50-share/) Holders of existing PolyPid warrants will exercise them for $26.7 million at $3.50 per share and receive new warrants at $4.50. The company ties the money to a Phase 3 trial whose effect size its release does not give. 2. 2025-01-17 Listings [PolyPid says $14.5 million private placement restored Nasdaq equity compliance](https://aibio.space/news/polypid-says-14-5-million-private-placement-restored-nasdaq-equity/) The company says stockholders' equity is now about $7.5 million, up from $2.2 million at September 30, 2024. Nasdaq staff will keep monitoring, and the company could face delisting if it cannot show compliance in its next periodic report. ## PolyPid at a glance - **Ticker**: PYPD - **Listing**: NASDAQ - **Country**: Israel - **Cash, Dec 31, 2025**: $6.4 million ### Related companies - [SciSparc](https://aibio.space/companies/scisparc/) NASDAQ: SPRC - [PRF Technologies](https://aibio.space/companies/prf-technologies/) NASDAQ: PRFX - [Silexion Therapeutics](https://aibio.space/companies/silexion-therapeutics/) NASDAQ: SLXN - [BioLineRX](https://aibio.space/companies/biolinerx/) TASE: BLRX - [Entera Bio](https://aibio.space/companies/entera-bio/) NASDAQ: ENTX - [Purple Biotech](https://aibio.space/companies/purple-biotech/) TASE: PPBT - [Nasus Pharma](https://aibio.space/companies/nasus-pharma/) AMEX: NSRX - [Redhill Biopharma](https://aibio.space/companies/redhill-biopharma/) NASDAQ: RDHL ### Also on NASDAQ - [SciSparc](https://aibio.space/companies/scisparc/) SPRC - [Precigen](https://aibio.space/companies/precigen/) PGEN - [Rallybio](https://aibio.space/companies/rallybio/) RLYB - [ORGANIGRAM GLOBAL INC.](https://aibio.space/companies/organigram-global/) OGI - [iTonic Holdings](https://aibio.space/companies/itonic/) ITOC - [ENDRA Life Sciences](https://aibio.space/companies/endra-life-sciences/) NDRA ## PolyPid annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$23.8 million](https://www.sec.gov/Archives/edgar/data/1611842/000121390026020370/) | [$22.8 million](https://www.sec.gov/Archives/edgar/data/1611842/000121390026020370/) | | Net income (loss) | [-$34.2 million](https://www.sec.gov/Archives/edgar/data/1611842/000121390026020370/) | [-$29.0 million](https://www.sec.gov/Archives/edgar/data/1611842/000121390026020370/) | | Cash from operations | [-$27.9 million](https://www.sec.gov/Archives/edgar/data/1611842/000121390026020370/) | [-$22.0 million](https://www.sec.gov/Archives/edgar/data/1611842/000121390026020370/) | | Cash and equivalents | [$6.4 million](https://www.sec.gov/Archives/edgar/data/1611842/000121390026020370/) | [$15.6 million](https://www.sec.gov/Archives/edgar/data/1611842/000121390026020370/) | Latest balance sheet, Dec 31, 2025 (20-F): cash and equivalents $6.4 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about PolyPid Was PolyPid delisted? Our latest story on this, dated Jan 17, 2025: "PolyPid says $14.5 million private placement restored Nasdaq equity compliance". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/polypid-says-14-5-million-private-placement-restored-nasdaq-equity/). Has PolyPid raised money recently? Our latest story on this, dated Jan 17, 2025: "PolyPid says $14.5 million private placement restored Nasdaq equity compliance". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/polypid-says-14-5-million-private-placement-restored-nasdaq-equity/). What is the ticker symbol of PolyPid? PolyPid Ltd. trades under the ticker PYPD on NASDAQ. Where is PolyPid listed? PolyPid Ltd. is listed on NASDAQ. What is the SEC CIK of PolyPid? The SEC Central Index Key (CIK) for PolyPid Ltd. is 1611842. Its filings are on SEC EDGAR. How many shares does PolyPid have outstanding? 18,204,002 shares as of 2025-12-31, per the cover page of its 20-F filed 2026-02-25. Which country or territory is PolyPid listed under? Our directory records PolyPid Ltd. under Israel. What does PolyPid do? Our directory classifies PolyPid Ltd. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of PolyPid? The ISIN recorded for PolyPid Ltd. is IL0011326795. Does aibio.space cover PolyPid? aibio.space lists PolyPid Ltd. among 2,820 public biotech companies and publishes its news here as stories appear. Where is PolyPid incorporated? SEC records list its state or country of incorporation as L3. Is PolyPid profitable? PolyPid Ltd. reported a net loss of $34.2 million for the fiscal year ended Dec 31, 2025, and used $27.9 million of cash in operations, per its annual report to the SEC. How much does PolyPid spend on research and development? $23.8 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does PolyPid have? $6.4 million in cash at Dec 31, 2025, per its 20-F. What is the latest PolyPid (PYPD) stock news? Our latest story on PolyPid, dated Nov 26, 2025: "PolyPid raises share sales program limit from $8,250,000 to $15,000,000". PolyPid can now sell up to $15,000,000 of ordinary shares through Oppenheimer & Co. Inc., up from $8,250,000, paying a 3.0% commission. Its shares closed at $3.68 on November 25, 2025, and the supplement does not say how much cash the company has. [Source](https://aibio.space/news/polypid-raises-share-sales-program-limit-8-250-000-15-000-000/). ## Investor discussion: PolyPid Members talk about PolyPid (PYPD). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at PolyPid, newest first. Each line links the filing it comes from. 1. 2025-11-26 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1611842/000121390025115476/ea0267379-424b5_poly.htm) 2. 2025-06-17 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611842/000121390025054964/ea024598401ex99-1_polypid.htm) 3. 2025-02-12 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611842/000121390025012486/ea023049301ex99-1_polypid.htm) 4. 2025-01-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611842/000121390025004603/ea0227903-6k_polypid.htm) 5. 2024-12-26 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611842/000121390024112468/ea022575301ex99-1_polypid.htm) 6. 2024-11-29 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611842/000121390024103942/ea022276601ex99-1_polypid.htm) 7. 2024-11-08 Financings Reported a financing. SEC Form 6-K. [Source](https://www.sec.gov/Archives/edgar/data/1611842/000121390024095892/ea0220358-6k_polypid.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:PYPD on TradingView](https://www.tradingview.com/symbols/NASDAQ-PYPD/). ## SEC filings and registration - **SEC name**: PolyPid Ltd. - **CIK**: 1611842 - **Industry (SIC)**: Surgical & Medical Instruments & Apparatus (3841) - **US tickers**: PYPD (Nasdaq) - **State or country of incorporation**: L3 - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer - **Business address**: 18 HASIVIM STREET, PETACH TIKVA, Israel, 4959376 - **Phone**: 972-74-7195700 - **Shares outstanding**: 18,204,002 as of 2025-12-31 (20-F filed 2026-02-25) ### Recent filings (8-K and 6-K are the company's own announcements) - [6-K](https://www.sec.gov/Archives/edgar/data/1611842/000121390026105492/ea0307316-6k_polypid.htm) filed 2026-10-01 - [6-K](https://www.sec.gov/Archives/edgar/data/1611842/000121390026105474/ea0307315-6k_polypid.htm) filed 2026-10-01 - [6-K](https://www.sec.gov/Archives/edgar/data/1611842/000121390026088439/ea0300231-6k_polypid.htm) filed 2026-08-12 - [6-K](https://www.sec.gov/Archives/edgar/data/1611842/000121390026088040/ea0301528-6k_poly.htm) filed 2026-08-12 - [6-K](https://www.sec.gov/Archives/edgar/data/1611842/000121390026082564/ea0299642-6k_polypid.htm) filed 2026-07-29 - [6-K](https://www.sec.gov/Archives/edgar/data/1611842/000121390026079808/ea0298559-6k_polypid.htm) filed 2026-07-21 - [6-K](https://www.sec.gov/Archives/edgar/data/1611842/000121390026078318/ea0297818-6k_polypid.htm) filed 2026-07-15 - [6-K](https://www.sec.gov/Archives/edgar/data/1611842/000121390026067311/ea0294092-6k_polypid.htm) filed 2026-06-10 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001611842), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details PolyPid Ltd. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker PYPD, recorded under Israel. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: PolyPid Ltd. - **Ticker**: PYPD - **Listing**: NASDAQ - **Country or territory**: Israel - **Business scope**: Pharmaceuticals: Major - **ISIN**: IL0011326795 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-PYPD/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/polypid/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "PolyPid (PYPD) news: delisting and offering", 2026-10-31, https://aibio.space/companies/polypid/